These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 18698872)

  • 1. Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.
    Liechti ME; Markou A
    CNS Drugs; 2008; 22(9):705-24. PubMed ID: 18698872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.
    Li X; Semenova S; D'Souza MS; Stoker AK; Markou A
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):554-65. PubMed ID: 23752091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabotropic glutamate receptor 5 as a potential target for smoking cessation.
    Chiamulera C; Marzo CM; Balfour DJK
    Psychopharmacology (Berl); 2017 May; 234(9-10):1357-1370. PubMed ID: 27847973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "stop" and "go" of nicotine dependence: role of GABA and glutamate.
    D'Souza MS; Markou A
    Cold Spring Harb Perspect Med; 2013 Jun; 3(6):. PubMed ID: 23732855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.
    Cross AJ; Anthenelli R; Li X
    Biol Psychiatry; 2018 Jun; 83(11):947-954. PubMed ID: 29301614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.
    Kenny PJ; Gasparini F; Markou A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1068-76. PubMed ID: 12805481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting glutamate homeostasis for potential treatment of nicotine dependence.
    Alasmari F; Al-Rejaie SS; AlSharari SD; Sari Y
    Brain Res Bull; 2016 Mar; 121():1-8. PubMed ID: 26589642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous opioid system: a promising target for future smoking cessation medications.
    Norman H; D'Souza MS
    Psychopharmacology (Berl); 2017 May; 234(9-10):1371-1394. PubMed ID: 28285326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double target concept for smoking cessation.
    Wu J
    Acta Pharmacol Sin; 2010 Sep; 31(9):1015-8. PubMed ID: 20711220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
    Liechti ME; Markou A
    Eur J Pharmacol; 2007 Jan; 554(2-3):164-74. PubMed ID: 17113075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal.
    Ashare RL; Schmidt HD
    Expert Opin Drug Discov; 2014 Jun; 9(6):579-94. PubMed ID: 24707983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats.
    Liechti ME; Markou A
    Biochem Pharmacol; 2007 Oct; 74(8):1299-307. PubMed ID: 17601493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments.
    D'Souza MS; Markou A
    Addict Sci Clin Pract; 2011 Jul; 6(1):4-16. PubMed ID: 22003417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide systems and new treatments for nicotine addiction.
    Bruijnzeel AW
    Psychopharmacology (Berl); 2017 May; 234(9-10):1419-1437. PubMed ID: 28028605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation.
    Markou A; Paterson NE; Semenova S
    Ann N Y Acad Sci; 2004 Oct; 1025():491-503. PubMed ID: 15542754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of NMDA receptor antagonists in nicotine tolerance, sensitization, and physical dependence: a preclinical review.
    Jain R; Mukherjee K; Balhara YP
    Yonsei Med J; 2008 Apr; 49(2):175-88. PubMed ID: 18452252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats.
    Li X; D'Souza MS; Niño AM; Doherty J; Cross A; Markou A
    Psychopharmacology (Berl); 2016 May; 233(10):1801-14. PubMed ID: 26873083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate: the new frontier in pharmacotherapy for cocaine addiction.
    Uys JD; LaLumiere RT
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):482-91. PubMed ID: 19128205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin receptors as potential targets for modulation of nicotine use and dependence.
    Fletcher PJ; Lê AD; Higgins GA
    Prog Brain Res; 2008; 172():361-83. PubMed ID: 18772042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
    Fagerström K; Balfour DJ
    Expert Opin Investig Drugs; 2006 Feb; 15(2):107-16. PubMed ID: 16433591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.